title: Tumor necrosis factor-alpha increases after corticotropin-releasing hormone administration in Cushing's disease. In vivo and in vitro studies.
abstract: The aim of this study was to evaluate the effect of acute human corticotropin (ACTH)-releasing hormone (CRH) administration (100 micrograms, as i.v. bolus) on tumor necrosis factor-alpha (TNF alpha) levels in the inferior petrosal sinuses and in the peripheral blood of 7 patients with Cushing's disease subjected to diagnostic inferior petrosal sinus sampling. Blood samples for ACTH, beta-endorphin (beta-EPH) and TNF alpha were collected from inferior petrosal sinuses and periphery simultaneously. In addition, TNF alpha concentrations were measured after CRH administration (10 nmol/l, 100 nmol/l and 1 mumol/l) in culture medium from primary cultures obtained in 3 of 7 patients. At baseline, plasma ACTH and beta-EPH levels were significantly higher in the inferior petrosal sinus ipsilateral to the ACTH-secreting adenoma than in the contralateral one and in the periphery (p < 0.001) whereas no significant difference was found as far as serum TNF alpha levels were concerned. CRH administration caused a significant increase of ACTH (p < 0.001), beta-EPH (p < 0.01) and TNF alpha (p < 0.01) levels greater in the ipsilateral inferior petrosal sinus than in the contralateral one and in the periphery. In addition, CRH increased ACTH, beta-EPH and TNF alpha levels in the culture medium of three ACTH-secreting tumors at the doses of 100 nmol/l and 1 mumol/l (greater than 300, 200 and 110% of baseline pretreatment incubation levels, respectively). These data suggest that CRH may increase TNF alpha concentrations in the inferior petrosal sinus ipsilateral to the ACTH-secreting adenoma and in the peripheral blood as well. In addition, it stimulated TNF alpha release both in vivo and in vitro. These findings suggest the possibility that an imbalanced intrapituitary TNF alpha production can be detected in ACTH-secreting adenomas.
authors.affiliation: Department of Molecular and Clinical Endocrinology and Oncology, Federico II University, Naples, Italy.
authors.forename: B
authors.initials: B
authors.lastname: Merola
authors.forename: S
authors.initials: S
authors.lastname: Longobardi
authors.forename: A
authors.initials: A
authors.lastname: Colao
authors.forename: C
authors.initials: C
authors.lastname: Di Somma
authors.forename: D
authors.initials: D
authors.lastname: Ferone
authors.forename: F
authors.initials: F
authors.lastname: Di Rella
authors.forename: R
authors.initials: R
authors.lastname: Pivonello
authors.forename: V
authors.initials: V
authors.lastname: Covelli
authors.forename: L
authors.initials: L
authors.lastname: Annunziato
authors.forename: G
authors.initials: G
authors.lastname: Lombardi
mesh_terms: D000236:Adenoma / Q000378:metabolism; D000324:Adrenocorticotropic Hormone / Q000097:blood / Q000378:metabolism; D000328:Adult; D003346:Corticotropin-Releasing Hormone; D003480:Cushing Syndrome / Q000097:blood*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D017591:Petrosal Sinus Sampling; D010911:Pituitary Neoplasms / Q000378:metabolism; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism*; D001615:beta-Endorphin / Q000097:blood
chemical_list: D014409:Tumor Necrosis Factor-alpha; D001615:beta-Endorphin; D000324:Adrenocorticotropic Hormone; D003346:Corticotropin-Releasing Hormone